GLP-1 Agonists and Athletic Performance: What We Know (and Don't Know) Research specific to endurance athletes and GLP-1 RAs is extremely limited
Though hed seen multiple therapists for anxiety and depression over the years and even discussed his weight, no one ever brought up his eating behaviors
(2015) Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum
GLP-1 medications carry risks including pancreatitis, gallbladder disease, and potential thyroid C-cell tumours based on animal studies
Obesity is not only a major risk factor for the development of T2D but also a risk factor for developing cardiovascular disease, sleep apnea and chronic pulmonary disease, various cancer manifestations, osteoarthritis, reflux disease, gallstones, nonalcoholic steatohepatitis (NASH), and depression (1822)